- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03860792
Therapeutic Diets in Alzheimer's Disease (TDAD)
September 27, 2023 updated by: Russell Swerdlow, University of Kansas Medical Center
By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica Keller, MS
- Phone Number: 913-588-5355
- Email: kkali17@kumc.edu
Study Contact Backup
- Name: Matthew Taylor, PhD
- Phone Number: 913-588-5363
- Email: mtaylor3@kumc.edu
Study Locations
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Recruiting
- Clinical and Translational Science Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 88 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of AD by current McKhann et al. criteria
- CDR global score of 0.5 or 1
- Agreed cooperation from an appropriate study partner
- Speaks English as primary language
- Age 50 to 90
- No medication changes within the past 30 days
Exclusion Criteria:
- Resides in a nursing home or dementia special care unit, or cannot control diet
- A potentially confounding serious medical risk including insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
- Participating in another clinical trial or using an investigational drug or therapy within 30 days of the Screening Visit
- A history of renal stones
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketogenic Diet
Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy).
The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily.
Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus.
After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
|
Three-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
|
Active Comparator: Therapeutic Lifestyles Changes Diet
Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet.
The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy.
Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy.
Cholesterol consumption will be ≤200mg per day.
Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
|
Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive performance on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCog11)
Time Frame: Baseline, 12 Weeks
|
Cognitive performance will be assessed by a psychometrician using the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCog11).
The ADAS-Cog is an Alzheimer's disease specific, multi-domain cognitive assessment scored from 0-70 points with higher scores indicating poorer cognitive performance.
|
Baseline, 12 Weeks
|
Change in cognitive performance on the Mini-Mental State Exam (MMSE)
Time Frame: Baseline, 12 Weeks
|
Global cognitive performance will be assessed by a psychometrician using the Mini-Mental State Exam (MMSE).
The MMSE is a brief cognitive questionnaire with a maximum score of 30 points where higher scores indicate better cognitive performance.
|
Baseline, 12 Weeks
|
Change in cognitive performance on the Logical Memory Test (LMT)
Time Frame: Baseline, 12 Weeks
|
The Logical Memory, subtest of the WMS-R is a standardized assessment of narrative episodic memory.
A short story is orally presented, and the examinee is asked to recall the story immediately.
|
Baseline, 12 Weeks
|
Change in cognitive performance by Stroop test
Time Frame: Baseline, 12 Weeks
|
Reaction time and accuracy will be assessed by a psychometrician using the Stroop test.
|
Baseline, 12 Weeks
|
Change in Clinical Dementia Rating (CDR)
Time Frame: Baseline, 12 Weeks
|
The Clinical Dementia Rating is a 5-point scale (CDR 0, 0.5, 1, 2, and 3) used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias.
CDR 0 indicates no dementia and higher values indicate more severe dementia.
The scores of all six domains are averaged to form a global CDR score.
Change in score from baseline to 3 months will be assessed.
|
Baseline, 12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cerebral concentration of N-Acetylaspartate (NAA)
Time Frame: Baseline, 12 Weeks
|
Concentration of cerebral N-Acetylaspartate is measured using magnetic resonance spectroscopy in a 3T clinical scanner.
|
Baseline, 12 Weeks
|
Change in blood platelet mitochondrial function
Time Frame: Baseline, 6 Weeks, 12 Weeks
|
Cytochrome c oxidase activity of blood platelets will be determined as a pseudo first order-rate constant (sec-1/mg protein) by measuring the oxidation of reduced cytochrome c at 550 nm.
|
Baseline, 6 Weeks, 12 Weeks
|
Change in self-reported symptoms by study partner
Time Frame: Baseline, 6 Weeks, 12 Weeks
|
Severity of symptoms will be measured via a self-reported symptoms questionnaire, answered by participant study partners.
|
Baseline, 6 Weeks, 12 Weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of days positive for urinary ketone production
Time Frame: Daily for 90 days (the length of the diet intervention)
|
Participants will measure and report daily urinary ketone status using Ketostix (Bayer, Germany).
|
Daily for 90 days (the length of the diet intervention)
|
Change in blood ketone levels induced by ketogenic diet
Time Frame: Baseline, 6 Weeks, 12 Weeks
|
We will measure serum beta-hydroxybutyrate levels.
|
Baseline, 6 Weeks, 12 Weeks
|
Dietary intake characterization prior to and after ketogenic diet initiation
Time Frame: Baseline, 6 Weeks, 12 Weeks
|
Changes in food and nutrient intake will be assessed by monthly 3-day food records completed by participant study partners.
|
Baseline, 6 Weeks, 12 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 29, 2019
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
November 30, 2024
Study Registration Dates
First Submitted
February 28, 2019
First Submitted That Met QC Criteria
February 28, 2019
First Posted (Actual)
March 4, 2019
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00143457
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Ketogenic Diet
-
Shriners Hospitals for ChildrenUniversity of HawaiiCompleted
-
University of PittsburghBaszucki Brain Research FundRecruitingBipolar DisorderUnited States
-
University of Roma La SapienzaCompleted
-
Kuopio University HospitalDeakin UniversityRecruitingPsychotic Disorders | Schizophrenia | Psychosis | Psychosis; AcuteFinland
-
Mid-Atlantic Epilepsy and Sleep Center, LLCUnknown
-
University of FloridaRecruitingSeizuresUnited States
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; Vanderbilt University Medical... and other collaboratorsActive, not recruiting
-
University of Maryland, BaltimoreRecruiting
-
Ohio State UniversityRecruiting
-
University of PadovaUniversity of Palermo; Universidade Federal de GoiasCompleted